Brief: ARCA Biopharma Retains Ladenburg Thalmann To Support Strategic Options Review
05/05/2022 23:48
May 5 (Reuters) - ARCA Biopharma Inc ABIO.O :
* ARCA BIOPHARMA RETAINS LADENBURG THALMANN TO SUPPORT
STRATEGIC
OPTIONS REVIEW
Source text for Eikon: ID:nGNX9BHPv
Further company coverage: ABIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oruka Therapeutics
See all newsOruka falls after reporting mid-stage data for psoriasis drug
Brief: Oruka Therapeutics Announces Positive Week 28 Data For Orka-001 From The Ongoing Everlast-A Trial Showing Deepening Of Responses Without Additional Dosing
Brief: Oruka Therapeutics Appoints Todd Edwards As Chief Commercial Officer
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Oruka Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary